Cite
HARVARD Citation
Salhotra, A. et al. (2021). Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA‐Ven) or liposomal daunorubicin‐cytarabine (CPX‐351). American journal of hematology. 96 (6), pp. E196-E200. [Online].